ADAM21P1: A Promising Drug Target and Biomarker for the Treatment of Inflammatory Neurodegenerative Diseases

Target Name: ADAM21P1

NCBI ID: G145241

ADAM21P1

Other Name(s): ADAM21P | ADAM metallopeptidase domain 21 pseudogene 1

ADAM21P1: A Promising Drug Target and Biomarker for the Treatment of Inflammatory Neurodegenerative Diseases

Introduction

Inflammatory neurodegenerative diseases, such as multiple sclerosis, rheumatoid arthritis, and neuroinflammatory bowel disease (NAIAD), have a significant impact on the daily life of patients. These conditions cause chronic pain, inflammation, and damage to various tissues and organs, leading to significant morbidity and mortality. The development of new treatments is crucial for improving the quality of life of patients. One of the promising drug targets in this context is ADAM21P1, a G protein-coupled receptor (GPCR) that has been identified as a potential therapeutic target in the treatment of inflammatory neurodegenerative diseases.

ADAM21P1: Structure and Function

The ADAM21P1 gene, located on chromosome 12, encodes a protein that belongs to the ADAM (Aquaporin) family. This family of transmembrane proteins plays a crucial role in water transport and has been implicated in various physiological processes, including modulating pain, inflammation, and vasodilation. The ADAM21P1 gene was first identified in 2008 and has been shown to encode a 21-kDa protein that displays partial agonistic activity for several GPCRs, including endothelin (ET) and malvidin (JAK) receptors.

The ADAM21P1 protein is composed of a transmembrane domain, a catalytic domain, and an intracellular loop. The transmembrane domain is responsible for the protein's ability to interact with GPCRs, while the catalytic domain is responsible for the protein's catalytic activity. The intracellular loop, also Known as the coiled-coil domain, plays a role in the protein's stability and functions as a scaffold.

ADAM21P1 has been shown to modulate various physiological processes, including pain perception, inflammation, and blood pressure. For example, studies have shown that ADAM21P1 can reduce pain perception in experimental animals and human patients with neuroinflammatory bowel disease (NAIAD). Additionally, the protein has been shown to increase inflammation in response to malvidin, a potent anti-inflammatory agent, suggesting that it may have a pro-inflammatory role.

Due to its potential role in modulating pain and inflammation, ADAM21P1 has been identified as a drug target in the treatment of inflammatory neurodegenerative diseases. Several studies have shown that blocking the activity of ADAM21P1 can lead to improved clinical outcomes in animal models of NAIAD and other inflammatory neurodegenerative diseases.

The Discovery and Validation of ADAM21P1 as a Drug Target

The identification of ADAM21P1 as a potential drug target is based on several studies that have demonstrated its ability to modulate pain and inflammation. One of the earliest studies was a high-throughput screening (HTS) assay using a library of small molecules. This assay allowed researchers to identify several compounds that interacted with ADAM21P1 and inhibited its activity.

Following up on these findings, researchers have conducted more in-depth studies to validate the potential of these compounds as therapeutic agents. One of the most promising compounds identified in these studies is P120, a small molecule that inhibits the activity of ADAM21P1 and has been shown to be effective in animal models of NAIAD.

To further validate the effectiveness of P120, researchers conducted a clinical trial in which patients with NAIAD were treated with P120. The results of this trial showed that treatment with P120 significantly improved pain relief and reduced inflammation in patients with NAIAD compared to a placebo.

In addition to P120, other compounds that have been shown to interact with ADAM21P1 and may have potential as

Protein Name: ADAM Metallopeptidase Domain 21 Pseudogene 1

The "ADAM21P1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ADAM21P1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets